PRO 2000 News
Most Popular PRO 2000 Story
Indevus HIV gel misses Phase III endpoint
Indevus announced Phase III results from an NIH-funded trial of PRO 2000, the company's vaginal microbicide for HIV prevention. Though women using the microbicide experienced a 30 percent lower risk Read more...
Latest Headlines
- February 9, 2009
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
